Key highlights
• Botanix has received confirmation that the NDA application for Sofpironium Bromide is suitable
for substantive review and no filing, review issues were identified
• FDA also confirmed that they do not believe that an advisory committee meeting is required to
discuss the application and that the mid-cycle review meeting remains on track for 1Q 2023
• With the formal NDA filing for Sofpironium Bromide now accepted by FDA and a standard
review period confirmed, approval for the product remains on track for 3Q 2023
Ann: Confirmation Sofpironium Bromide NDA Formally Under Review, page-3
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.020(6.25%) |
Mkt cap ! $615.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 34.0¢ | 32.0¢ | $1.776M | 5.339M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 118187 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 698385 | 8 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |